Paller AS, Gold LS, Soung J, et al. - This study was undertaken to investigate effectiveness and patient-reported outcomes from a phase IIb, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis. Researchers conducted phase IIb, double-blind, vehicle-controlled study to randomize adolescents and adults with atopic dermatitis (AD) to receive tapinarof cream 0.5%, 1%, or vehicle, once or twice daily for 12 weeks with 4-week follow-up. Investigator Global Assessment, Eczema Area and Severity Index, body-surface area affected, pruritus numeric rating scale scores, subject impressions of AD and pruritus symptom severity, and Patient-Oriented Eczema Measure scores were the outcomes.191/247 individuals were randomized to complete the study. For AD, tapinarof was found to be a potential important advance in topical medicine development.